Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma

Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Study ID: NCT00126243
Phase: PHASE2
Status: Terminated

Conditions

AIDS Related Lymphoma

Eligibility Criteria

Sex: ALL
Age: 18 Years - 75 Years
Healthy Volunteers: Not accepted

Interventions

rituximab — DRUG
CHOP — DRUG

Study Details

Most treatment procedures in AIDS-related lymphomas disclose a relatively poor outcome for patients with low response rates, high number of relapses and AIDS events. The addition of rituximab to the standard regimen - CHOP could improve the outcome of these patients. The aim of the trial is to evaluate the safety and efficacy of rituximab when added to the CHOP regimen in patients with newly diagnosed AIDS-related non-Hodgkin lymphoma.

Key Dates

Start date: Jan 31, 1999
Status verified: Aug 2005
Completion: Oct 31, 2003

Study Design

Enrollment: 60 participants
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Primary Outcome Measure

Evaluate the response rate of lymphoma treated